These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 3123597)

  • 1. Selegiline in the early and late phases of Parkinson's disease.
    Csanda E; Tárczy M
    J Neural Transm Suppl; 1987; 25():105-13. PubMed ID: 3123597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (-)Deprenyl in the treatment of decompensated Parkinson's disease.
    Csanda E; Tárczy M; Takáts A
    J Neural Transm Suppl; 1986; 22():247-52. PubMed ID: 3097259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-deprenyl in the treatment of Parkinson's disease.
    Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G
    J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with selegiline in the treatment of Parkinson's disease.
    Poewe W; Gerstenbrand F; Ransmayr G
    J Neural Transm Suppl; 1987; 25():131-5. PubMed ID: 3123599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK
    J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current controversies in the use of selegiline hydrochloride.
    Lees AJ
    J Neural Transm Suppl; 1987; 25():157-62. PubMed ID: 3123602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
    Birkmayer W; Birkmayer GD
    J Neural Transm Suppl; 1986; 22():219-25. PubMed ID: 3097256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
    Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
    Golbe LI; Duvoisin RC
    J Neural Transm Suppl; 1987; 25():123-9. PubMed ID: 3123598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor.
    Przuntek H; Kuhn W
    J Neural Transm Suppl; 1987; 25():97-104. PubMed ID: 3123607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant drugs in the treatment of on-off phenomena in Parkinson's disease.
    Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Bihari K
    Adv Neurol; 1984; 40():549-56. PubMed ID: 6421113
    [No Abstract]   [Full Text] [Related]  

  • 14. ["Widening horizons" in the clinical application of selegiline].
    Kovács A
    Acta Pharm Hung; 1992 Sep; 62(5):259-64. PubMed ID: 1488911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The dopamine agonist, lisuride, in the therapy of Parkinson disease].
    Madeja UD
    Acta Histochem Suppl; 1992; 42():25-31. PubMed ID: 1584973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages.
    Giovannini P; Martignoni E; Piccolo I; Pacchetti C; Grassi MP; Nappi G; Caraceni T
    J Neural Transm Suppl; 1986; 22():235-46. PubMed ID: 3097258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline in the treatment of Parkinson's disease.
    Heinonen EH; Rinne UK
    Acta Neurol Scand Suppl; 1989; 126():103-11. PubMed ID: 2515715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
    Csanda E; Tárczy M
    Acta Neurol Scand Suppl; 1983; 95():117-22. PubMed ID: 6428143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.